Holen Sie sich die Stockscreener-App
3.6639
3.95%
0.1239
Schlusskurs vom Vortag:
$3.54
Offen:
$3.57
24-Stunden-Volumen:
6.96M
Relative Volume:
0.41
Marktkapitalisierung:
$1.94B
Einnahmen:
$74.68M
Nettoeinkommen (Verlust:
$-644.76M
KGV:
-2.4708
EPS:
-1.4829
Netto-Cashflow:
$-380.44M
1W Leistung:
+8.55%
1M Leistung:
+7.60%
6M Leistung:
-45.80%
1J Leistung:
-34.75%
1-Tages-Spanne:
$3.56
$3.73
1-Wochen-Bereich:
$3.23
$3.73
52-Wochen-Spanne:
$2.80
$7.18
Recursion Pharmaceuticals Inc Stock (RXRX) Company Profile
Firmenname
Recursion Pharmaceuticals Inc
Sektor
Branche
Telefon
(385) 269-0203
Adresse
41S RIO GRANDE STREET, SALT LAKE CITY
Compare RXRX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
3.67 | 1.87B | 74.68M | -644.76M | -380.44M | -1.4829 |
VRTX
Vertex Pharmaceuticals Inc
|
438.64 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
746.26 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
839.34 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
334.51 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
315.51 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Recursion Pharmaceuticals Inc Stock (RXRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-05-22 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2023-03-16 | Eingeleitet | Needham | Buy |
| 2022-09-16 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2022-04-18 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-03-04 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-09-21 | Eingeleitet | Berenberg | Buy |
| 2021-05-11 | Eingeleitet | BofA Securities | Buy |
| 2021-05-11 | Eingeleitet | Goldman | Neutral |
| 2021-05-11 | Eingeleitet | JP Morgan | Neutral |
| 2021-05-11 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2021-05-11 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Recursion Pharmaceuticals Inc Aktie (RXRX) Neueste Nachrichten
Recursion Pharmaceuticals Inc. (RXRX) partners with Citeline to develop AI-powered ClinTech platform - MSN
Recursion Pharmaceuticals (RXRX) down 16.5% since last earnings report: Can it rebound? - MSN
Recursion Pharmaceuticals Stock (RXRX) Opinions on Upcoming Earnings and AI Developments - Quiver Quantitative
symbol__ Stock Quote Price and Forecast - CNN
Recursion And Citeline Deepen AI Trial Data Tie For RXRX Investors - Yahoo Finance
Why Recursion (RXRX) Is Up 10.8% After Deepening Citeline Partnership To Power AI-Driven Clinical Trials - Sahm
Recursion Pharmaceuticals, Inc. (RXRX) Stock Price, News, Quote & History - Yahoo! Finance Canada
RXRX|Recursion Pharmaceuticals Inc|Price:3.369|Chg%:0.09 - TradingKey
Recursion Pharmaceuticals (RXRX) stock declines while market improves: Some information for investors - MSN
Recursion Pharmaceuticals, Inc. (RXRX) stock price, news, quote and history - Yahoo Finance UK
Recursion Pharmaceuticals (RXRX) Stock Declines While Market Improves: Some Information for Investors - Yahoo Finance
Insider Sell Alert: Blake Borgeson Sells 30,000 Shares of Recurs - GuruFocus
Recursion names Vicki Goodman as CMO - MSN
Recursion to Participate in Upcoming Investor Conferences - marketscreener.com
Recursion Pharmaceuticals Inc. (RXRX) Partners with Citeline to Develop AI-Powered ClinTech Platform - Insider Monkey
Fund Flows: Is Recursion Pharmaceuticals Inc forming a double bottom2026 Snapshot & Advanced Swing Trade Entry Alerts - baoquankhu1.vn
Recursion Pharmaceuticals, Inc. (RXRX) latest stock news and headlines - au.finance.yahoo.com
Does AI Data Deal And New CMO Hire Change The Bull Case For Recursion (RXRX)? - Sahm
Recursion Pharmaceuticals (RXRX) beats stock market upswing: What investors need to know - MSN
Recursion Pharmaceuticals (RXRX) Beats Stock Market Upswing: What Investors Need to Know - Yahoo Finance
Director at Recursion (NASDAQ: RXRX) awarded 3,268 shares - Stock Titan
Expanded Citeline Data Partnership and CMO Transition Could Be A Game Changer For Recursion Pharmaceuticals (RXRX) - Yahoo Finance
A Look At Recursion Pharmaceuticals (RXRX) Valuation As Investor Narratives Diverge - Sahm
1 Beaten-Down AI Stock to Buy and 1 to Avoid - Yahoo Finance
Citeline expands partnership with Recursion for clinical trials - investing.com
Recursion Expands Strategic Partnership with Citeline to Advance Its AI-Enabled ClinTech Platform - GlobeNewswire Inc.
2 AI Healthcare Stocks to Buy Right Now - The Globe and Mail
RXRX Stock Price, Quote & Chart | RECURSION PHARMACEUTICALS-A (NASDAQ:RXRX) - ChartMill
RXRX SEC FilingsRecursion Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms - stocktitan.net
Recursion Pharmaceuticals (RXRX) Surges 14% Ahead of Earnings - MSN
Recursion Pharmaceuticals (NASDAQ:RXRX) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Recursion Pharmaceuticals stock hits 52-week low at $2.98 By Investing.com - Investing.com Australia
Finanzdaten der Recursion Pharmaceuticals Inc-Aktie (RXRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Recursion Pharmaceuticals Inc-Aktie (RXRX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Borgeson Blake | Director |
Apr 07 '26 |
Sale |
3.10 |
30,000 |
93,000 |
6,229,863 |
1.80%
0.71%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):